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Background: An increased risk of breast cancer following radiotherapy for Hodgkin lymphoma (HL) has
now been robustly established. In order to estimate the dose–response relationship more accurately,
and to aid clinical decision making, a retrospective estimation of the radiation dose delivered to the site
of the subsequent breast cancer is required.
Methods: For 174 Dutch and 170 UK female patients with breast cancer following HL treatment, the 3-
dimensional position of the breast cancer in the affected breast was determined and transferred onto a
CT-based anthropomorphic phantom. Using a radiotherapy treatment planning system the dose distribu-
tion on the CT-based phantom was calculated for the 46 different radiation treatment field set-ups used
in the study population. The estimated dose at the centre of the breast cancer, and a margin to reflect
dose uncertainty were determined on the basis of the location of the tumour and the isodose lines from
the treatment planning. We assessed inter-observer variation and for 47 patients we compared the
results with a previously applied dosimetry method.
Results: The estimated median point dose at the centre of the breast cancer location was 29.75 Gy (IQR
5.8–37.2), or about 75% of the prescribed radiotherapy dose. The median dose uncertainty range was
5.97 Gy. We observed an excellent inter-observer variation (ICC 0.89 (95% CI: 0.74–0.95)). The absolute
agreement intra-class correlation coefficient (ICC) for inter-method variation was 0.59 (95% CI: 0.37–
0.75), indicating (nearly) good agreement. There were no systematic differences in the dose estimates
between observers or methods.
Conclusion: Estimates of the dose at the point of a subsequent breast cancer show good correlation
between methods, but the retrospective nature of the estimates means that there is always some uncer-
tainty to be accounted for.
 2017 The Authors. Published by Elsevier Ireland Ltd on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Several publications have demonstrated a dose-dependent
increased risk of breast and other cancers following chest radiation
exposure in women, including therapeutic radiation for a first
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of the shape of the dose–response for the risk of radiation-
induced primary breast cancer following radiotherapy for Hodgkin
Lymphoma (HL), a reliable estimate of the received dose to the site
of the breast tumour is required [11]. Although patients currently
treated for HL with radiotherapy have computer tomography
(CT) planning scans and individual 3-dimensional dosimetry, this
is not the case for patients with breast cancer who were treated
for HL before 2004. Radiation dose effects can be estimated using
nominal data (radiation yes/no), and information on the prescribed
dose to the target volume. In our previous study evaluating the
dose response effect, we applied a technique to estimate retrospec-
tively the dose at the point of the subsequent breast cancer more
specifically [10]. For this method, described in detail by Stovall
et al. [12] simulation of the prescribed radiotherapy was per-
formed. Using the original simulation radiographs and the records
from the radiation treatment charts, the absorbed dose at the site
of the breast cancer was determined using a combination of three
techniques: (1) calculation using a three dimensional (3D) mathe-
matical computer model based on measurements made in a water
or polystyrene phantom for different beam energies and treatment
machines-used for breast tumour sites out of field; (2) direct mea-
surements in an anthropomorphic phantom constructed of tissue
equivalent material, and (3) calculation of dose using a treatment
planning system (ADAC Pinnacle System, Philips Radiation Oncol-
ogy Systems, Milpitas, CA). For brevity, in the rest of this report,
we will refer to this method as the ‘‘radiograph-based” method.
However, a limitation of this technique is that the original simu-
lation radiographs are required, and for the majority of patients
treated one or more decades ago, these are now no longer avail-
able. An alternative method utilizes anthropomorphic phantoms
from radiotherapy planning CT scans for retrospective recon-
struction of the dose to voxels inside and outside the treated vol-
ume, which takes into account leakage and scattered radiation
from the machine head and within the patient [13,14]. Here we
describe the further development of this method specifically
for estimation of the dose at the site of breast cancer develop-
ment following HL radiotherapy utilizing individual patient
and treatment data in three dimensions. In the rest of the
manuscript we will refer to this as the ‘‘CT phantom-based”
method.
The dosimetry described in this paper was performed as part of
a study to estimate the radiation dose–response for breast cancer
induction following treatment for HL using the case-control-
matched-location method, as described by Langholz et al. [15], for
case-control studies nested in cohorts of 5-year HL survivors from
the Netherlands (updated from [5,10]) and the UK [16]. This
method entails determining the location of the breast cancer in
the affected breast among cases, and estimating the dose to this
point from the radiation treatment given previously for HL. The
dose to the same location in the breast is also estimated from
the radiotherapy treatment of control patients, who are HL sur-
vivors matched for several criteria (age at HL, HL treatment year,
treatment centre) but without breast cancer after the same
follow-up as the corresponding case with breast cancer. For the
radiograph-based method, it is necessary to retrieve the patients’
original simulation radiographs. As these are no longer available
for all the patients included in the study, we developed a dosimetry
method based on a library of generic radiation field types and set-
ups. The dose–effect relationship derived from the data described
in this report (including the influence of chemotherapy and ovar-
ian hormone exposure), will be reported separately. Here we
describe in detail the method developed for the radiation
dosimetry.Methods
The radiation dosimetry was based on a voxel-based anthropo-
morphic phantom from a radiotherapy planning CT scan obtained
from a typical 21 year-old female HL patient, with height 1.70 m
and weight 67 kg. (Fig. 1). The scan was acquired in supine position
on a flat couch top with the arms abducted alongside the head. We
first established a library of the different shapes and combinations
of radiation field set-ups based on the treatment charts of patients
who had developed breast cancer following HL treatment and also
their controls without breast cancer. We drew the individual field
types onto a digitally reconstructed radiograph obtained from the
CT scan, simulating the original simulation radiographs at the time
of the HL treatment. There were variations in the shape and extent
of the fields depending on the techniques for individual shielding,
year of treatment, and also between radiotherapy centres. In total
46 radiation field types and combinations were used for dosimetry
with the planning system. Details of all field types are given in Sup-
plementary material. The three-dimensional (3-D) dose distribu-
tions were then simulated for each field set-up on the
anthropomorphic CT phantom, using Isogray treatment planning
system (TPS) (Dosisoft, Cachan, France). The 3-D dose distributions
were computed using the double decomposition Clarkson algo-
rithm with density heterogeneity correction with a voxel size of
5 mm. A radiation energy of 6 MV was assumed for all treatments.
The block transmission factor used was 0.04. As the prescribed
dose for the same field type varied per patient, the dose scale
was set as a percentage of the prescribed dose to the target volume.
The dose distribution was reported in 12 transversal planes at
1.5 cm intervals, from the second to the 10th thoracic vertebrae,
covering the whole breast tissue in the phantom (Fig. 1). Finally,
a pdf file with hyperlinks was produced for each typical field allow-
ing access to the dose distribution on a transversal CT slice by a
mouse click and thus provide an interactive and user friendly
dosimetry tool.
We first reviewed the HL medical and radiotherapy treatment
charts and simulation radiographs or other information to deter-
mine which field type was appropriate for each patient. There were
174 Dutch patients assessed among whom one case had breast
cancer but no previous radiotherapy. We then determined the
breast cancer location for all breast cancer cases. We used all the
medical and imaging information available from the medical chart
at the time of the diagnosis and treatment of the breast cancer. For
each breast cancer, we estimated the position of the centre of the
tumour in the breast, usually in relation to the nipple. We then
determined which slice level(s) on the anthropomorphic CT phan-
tom corresponded to the cancer location. On the appropriate slice
(s), the size and laterality of the cancer was then traced onto a
power-point image, scaled to the size of the actual patient, based
on the field separation mid-mediastinum (usually 16–18 cm)
reported on the chart. Where there seemed to be some discor-
dance, as with a very lateral tumour in a large breast, we adjusted
the position so that the tumour was always in the breast issue of
the phantom, rather than for example muscle or skin. Polaroid
photographs of the treatments set-up helped determine the rela-
tive position of the shielding blocks to the nipple, if available
(examples in Supplementary material). A second concomitant
breast cancer was present in 15 cases, 1 ipsi-lateral in a different
quadrant, and 14 contra-lateral. The position and size of these
tumours was also established. These data were included in the
analysis of the distribution of the cancer locations in the breast,
but for the dose–response analyses, only the dose estimation of
the largest invasive cancer was included. For the 170 cases from
the UK, we had less information on the radiation treatments deliv-
Fig. 1. Voxel-based anthropomorphic phantom from a radiotherapy planning CT scan obtained from a 21 year-old female adult. A: Example of field set-up type 11C, B:
location and size of the breast cancer in the left breast drawn on the appropriate position in the CT-based phantom with colour-wash of dose distribution. C: determination of
the position of subsequent breast cancer (BC) drawn onto the simulation radiograph of the individual patient (for use with the radiograph-based method).
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areas, the dose and the year of treatment, and no simulation radio-
graphs. One of the field types allocated to the Dutch patients was
then chosen based on the information available and the clinical
experience of NR who has clinical experience of treating HL
patients both in the UK and the Netherlands from the 1980’s,
and who also discussed earlier treatment fields with older col-
leagues. The UK cohort provided for all breast cancer cases detailed
information derived from the mammograms [16] with coordina-
tion points for quadrant, distance of the cancer from the nipple
and breast edge in Medial-Lateral-Oblique (MLO) and cranio-
caudal (CC) views, size of the breast and size of the cancer. For
the UK patients we had no other clinical sources of information
such as surgical or pathology reports, which we did have available
for the Dutch patients. All patient data was coded, removing indi-
vidual identification.
To take into account uncertainties in the estimate of the breast
cancer position we then added an uncertainty margin around the
tumour delineation. In some cases where we had full clinical,
pathological and imaging information, this margin was 0 cm. In
other cases where we only had information such as ‘‘lateral upper
quadrant”, we added up to 2 cm in three dimensions.
We registered the estimated dose at the centre of the cancer
from the isodose curves in the central slice covered by the cancer
position, and documented this as the point dose. We also regis-
tered the range of dose between the maximum and minimum pos-
sible dose at the breast cancer site taking into account the cancer
size, location and an uncertainty margin in 3 dimensions and called
this the dose uncertainty range. As a measure of inter-observervariation, a random sub-set of 22 cases were assessed again inde-
pendently by a second radiation oncologist (BA).
The breast cancer location according to ICD-10 definition [17]
was recorded for the UK and Dutch patients groups and according
to laterality.
For 47 cases included in an earlier study we had data available
to compare the inter-method variation in dose estimation with the
CT phantom-based method to that obtained with the radiograph-
based method [10].Statistical methods
Descriptive statistics were used to define the data from the two
cohorts. For comparison of the dose estimates a Mann-Whitney
test was applied. We evaluated variation between methods and
observers by estimating absolute-agreement Intra-class Correla-
tion Coefficients (ICC) using two-way random-effects models and
Bland–Altman [18,19] plots. We considered an ICC of >0.60 as
good, and >0.75 as excellent according to standard criteria [20].
The Chi-square statistic was applied to the decile data of the dose
uncertainty range.Results
The breast cancer position and dosimetry for 344 patients (174
Dutch and 170 UK patients) and a total of 359 individual cancers
was determined, showing that this approach was feasible, albeit
os
e
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determining the field type and breast cancer location.Po
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7Dosimetry
Table 1 and Supplementary Table 3 give the descriptive statis-
tics of the dose estimates at the central point of the breast cancer
(the point dose) for Dutch and UK patients, both combined and
separately. On average, the point dose was about 75% of the pre-
scribed dose. The distribution of point doses for the two groups
is illustrated in histograms in Fig. 2A and B. We observed a biphasic
distribution with a peak at the lower dose end and one at the
higher dose end, reflecting the fact that breast tissue was partially
under the shielding and partially in the full beams. There was a
higher median point dose estimate in the Dutch patients
(31.7 Gy) compared to the UK patients (28.5 Gy), p = 0.016, reflect-
ing a slightly higher average prescribed dose in the Dutch patients.an
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The ICC for inter-method variation was 0.59 (95% CI: 0.37–0.75),
indicating a (nearly) good agreement (scatter plot in Fig. 2C). The
Bland–Altman Plot (Fig. 2D), showed no systematic differences in
dose estimates. The mean difference in dose estimate was
3.7 Gy, standard deviation 14.7 Gy, levels of agreement 33.1
to 25.7 Gy. We examined in detail the ‘‘outlier” cases from the scat-
ter plots. The reason for the apparent discrepancy in most cases
was the estimation of the tumour position relative to a shielding
block edge. This could be due to assessment of the position of
the tumour in the breast, or the position of the block relative to
the breast tissue. As the same researcher (NR) determined the
tumour position for both methods, this also reflects some intra-
observer variation.on
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We observed an excellent agreement between observers
regarding estimated radiation dose (ICC 0.89 (95% CI: 0.74–0.95))
as illustrated in Fig. 2E. Bland–Altman plots (Fig. 2F) showed that
there was no systematically higher or lower dose estimation
between observers. The mean difference in dose estimate was
0.9 Gy, standard deviation = 7.5 Gy, levels of agreement 6.6 to
8.4 Gy. The estimated position of the breast cancer could vary
between the observers by up to 2 cm and this could lead to varia-
tion in point dose estimate, especially if the position was near the
edge of shielding blocks. However, with one exception (case with a
multi-centric tumour) the cancer locations were all within the
uncertainty margin. There was a non-significant difference
between the two observers if this outlier was excluded from the
analysis.
We also quantified uncertainties in the dose estimates. The UK
patients had a significantly smaller dose uncertainty range, with a
median of 5.2 Gy (SD = 8.5 Gy) compared to 9.8 Gy (SD = 12.3 Gy)
for the Dutch patients, p < 0.001 (Fig. 2G and H), which we attri-
bute to the availability of solely mammographic information in
the UK patients, but more extensive and varied clinical sources of
information for the Dutch patients.Ta
bl
e
1
Ra
di
at
io
n
do
se
pr
es
cr
ip
ti
N m
ea
n
St
d
D
ev
ia
ti
on
M
in
im
u
m
M
ax
im
u
m
Pe
rc
en
ti
le
s
(m
ed
ia
n
)Tumour location
A schematic diagram representation of all 359 breast cancers
from both countries is given in Fig. 3 and the Supplementary mate-
rial. The majority of tumours were located in the upper and outer
quadrants.
Fig. 2. A: histogram of the distribution of the estimated point dose for UK patients. B: histogram of distribution of the estimated point dose for Dutch patients. C: Scatter plot
of inter-method variation between the radiograph-based versus the CT phantom-based method. D: Bland–Altman plot of inter-method variation. E: scatter plot of inter-
observer variation in dose estimate. F: Bland–Altman plot of variation between observers. G: histogram of dose uncertainty range for UK patients. H: histogram of dose
uncertainty range for Dutch patients.
24 N.S. Russell et al. / Clinical and Translational Radiation Oncology 7 (2017) 20–27
Fig. 3. Distribution of breast cancer locations in the breast according to ICD-10 codes, right and left breast separately, for UK and Dutch patients combined. Green: ICD-10
code for tumour locations in the right breast; blue: ICD-10 code for tumour locations in the left breast; red: percentage of tumours in specified location. Details of the ICD-10
coding system is given in supplementary material. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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This study provides important information on the reliability
and validity of the methods applied, showing good–excellent
agreement between methods and observers. One of the strengths
of our study is that we compared the dose estimates obtained
with the CT phantom-based method with a previously applied
method based on simulation radiographs (one frequently applied
previously by our group and others to determine the dose effect
relationship) [7,10,21]. In addition, we estimated the inter-
observer variation, which to our knowledge is unique to this
study. However, both the radiograph- and the CT phantom-
based methods have several limitations. Table 2 addresses the
main issues and considerations related to uncertainty, and
whether these factors generate a systematic effect on the dose
estimate. In other words, do they cause consistent under-, or
over-estimation of the dose at the site of the breast tumour?
We concluded that generally this was not the case, except for
the fact that the CT-phantom estimations were performed with
a CT in deep inspiration breath hold (DIBH). Aznar et al. [22] have
demonstrated a reduction in breast dose when using DIBH for
involved nodal irradiation for HL compared to free breathing
techniques.
The approach of applying various historical field types and set-
ups for dosimetry based on a CT-phantom obtained from a patient
of typical build was previously used by Taylor et al. [23,24] in
determining the dose received by heart structures from breast can-
cer radiotherapy. These data were then utilized to determine a
dose response relationship for ischemic heart disease by Darby
et al. [25]. It can be argued that this is a valid approach to generate
dosimetry data for establishing dose–response relationships, as
errors in estimation are unlikely to be systematic (this manu-
script). On the other hand, to estimate the individual risk of a sec-
ondary event more detailed individual dose parameters should be
determined [26].All methods used generate retrospective estimates, which
means that certain assumptions must be made. Ng and colleagues
have demonstrated a good correlation between dose estimates
from 2-D treatment planning information and actual CT-based 3-
D plans [27], suggesting that CT phantom-based method, which
is a hybrid of the two techniques, is probably a reasonable
approximation.Uncertainty quantification
Applying an uncertainty range makes the data as complete as
possible, but could affect the estimated dose–response relationship
because of the large variations of dose across some volumes either
due to large cancers or large uncertainty margins. We do not know
whether the cancers originate at one point in the centre of mass, or
indeed whether there is a field cancerization effect across a larger
portion of the breast tissue in general [28], or mediation through
bystander effects of breast stromal elements as suggested from
experimental data of Barcellos-Hoff et al. [29]. If this were the case,
then possibly a mean breast dose would be sufficient to estimate
risk, in analogy to the mean heart dose used for analysis of
radiation-induced cardiac disease [30]. Further, although some
tumours were screen-detected and quite small (5 mm), others
were large T3 tumours growing in almost the whole of the breast
over multiple quadrants, resulting in a large dose-gradient across
the tumour position from the HL radiotherapy. In the WECARE
study of asynchronous contra-lateral breast cancer [15] most sec-
ond breast cancers were detected early as the patients were under
regular screening following their first breast cancer diagnosis.
However, 99/708 were excluded from the analysis due to multiple
tumours in different locations, or single tumours that spanned
multiple locations, or lack of information on location. In our study
we included these tumour types by choosing the first largest
tumour as the index tumour, and utilizing clinical and pathology
Table 2
Comparison of uncertainties between CT-phantom and radiograph-based methods of retrospective dosimetry.
Uncertainty Issue with
CT
phantom-
based
method?
Systematic
effect on
dose
estimate?
YES/NO
Issue with
radiograph-
based
method?
Systematic
effect on
dose
estimate?
YES/NO
Details
Patient anatomy factors
Patient/phantom matching:
volume and shape of the
breast
Yes No Yes No Maraldo et al. [26] have demonstrated a inter-patient variation with a standard deviation of around 13% of the prescribed dose
for the dose to breast tissue from a simulated mantle field in 21 female patients.
With the radiograph method as the size and shape of the breasts is often visible on the radiograph, anthropomorphic phantom
can be modified for various breast sizes [12]
Size/shape of breast changes
with aging
Yes No Yes No Cannot be evaluated
Daily set-up uncertainty Yes No Yes No Daily set-up was on the basis of skin marks, portal films and off-line corrections. In earlier time periods loose shielding was
positioned daily on Perspex blocks in the beam. Later custom-made shielding was used, but there still could be daily shifts in
positioning
Position/shape of breast in prone
position
Yes No Yes No Same as patient/phantom matching (shape of the breast), but with specific change in breast shape.
For the radiograph method, the tumour position was drawn onto the AP radiograph in supine position, no correction was made
for changes in the prone position
Size of patient AP diameter of patient in cm taken from radiotherapy charts. Tumour size and position scaled to patient PA diameter with CT-
based method.
For radiograph method actual radiograph used and standard adult anthropomorphic phantom
Location, size, shape of tumour
in the breast
Yes No Yes No All available clinical and radiological data used for both methods. Size given in histology report used, otherwise size on
mammography or other imaging.
Size of tumour scaled to patient diameter recorded on the RT chart.
Radiograph-based method: only 2D information on position available for dosimetry.
Dose uncertainty range takes into account uncertainty in size/position/shape/quality of data available for localization.
Estimated centre of tumour used to determine point dose, but in large tumours this point may not be the point of origin of the
tumour
Use of CT scan with arms next to
head, actual treatments with
conventional simulation and
arms abducted 45–90
Yes No No No Could influence estimate especially in locations in lateral quadrants. Not an issue with radiograph-based method.
Actual quantification of this effect would require CT phantoms obtained from patients scanned with the arms abducted in an
extra wide bore scanner
Use of CT phantom with deep
inspiration Breath hold
(DIBH)
Yes Yes No No Deep inspiration causes diaphragm to move caudally, so the cranial border of the splenic field is more caudal relative to the left
breast, giving an underestimation of the dose to the lower quadrants. Aznar et al. [22] have demonstrated a reduction in mean
breast dose using DIBH free breathing for involved node radiotherapy following chemotherapy.
For the radiograph method, this factor not an issue, as the tumour position was drawn onto the simulator radiograph
Dose calculation factors
In some patients dose defined for
separate parts of the field e.g.
mediastinum, axilla, neck
Yes,
accounted
for
No No No For CT-based method, the dose reconstruction was based on one dose prescription for whole mantle field, on beam central axis.
Assessment of the dose to the tumour according to the prescription used for the part of the field closest to the tumour (axillary,
mediastinum, neck).
Not an issue with the radiograph method, as the whole treatment was simulated
Treatments with Cobalt/6 MV/
8 MV/10 MV photons. Model
dose estimate with 6 MV for
all patients
Yes No No No As tumour originates in breast tissue and not in skin, variations in build-up dose have little effect on dose estimation.
In the radiograph-based method, the dose distribution data took into account the radiation quality and output from the therapy
machine type that the patient was actually treated with.
Contribution of dose from boost
field to points outside boost
field
No,
accounted
for
No No,
accounted
for
No For the CT-based method, the contribution of dose from boost fields where no breast tissue was directly in the field was taken
account of by performing out of field dose calculation [13,14]. For the radiograph-based method out of field measurements were
performed [12]
Individual variation in head
leakage and scatter from
different machines
Yes No No,
accounted
for
No CT-based method: Individual variation in head leakage and scatter from different machines could not be taken account of. It was
considered that if the breast was relatively close to the field border (<30 cm), the in-patient scattering was predominant.
In the radiograph-based method, the dose distribution data took into account the radiation quality and output from the therapy
machine type that the patient was actually treated with
Observer variation
Determining position of tumour
in the breast relative to the
field
Yes,
quantified
No Yes No CT-based method: Inter-observer variation assessed by tumour localization determined by 2nd observer in sample of patients
was excellent.
Observer 1 for the CT based method also determined the tumour positions for the radiograph-based method
26
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more complete as we did not exclude the larger tumours.
Implications and future research
As a general discussion point, for the purposes of defining the
dose–response relationship, it is probably not very critical that
an exact reproduction is obtained per individual treatment, as long
as there is no systematic error. The dose–response estimate will
however be attenuated by known or unknown uncertainty in the
dose estimation. (Quantification of this attenuation has been
reported by our group in Krul et al. [31]). The situation is of course
different when one wants to estimate the breast cancer risk for an
individual patient based on her previously given treatment. There-
fore other methods will be more applicable. In ongoing research
we are currently applying the case-control-all-location method
[15] to this data-set. The comparison is between the cases’ breast
cancer dose and each of the cases’ non-cancer locations and the
doses at all the control subject locations. This method has the
advantage that data is incorporated on dose throughout the breast
volume. Also, the volume of the tumour in the breast can be incor-
porated into the analysis, thus avoiding the issue of whether the
point dose at the centre of the tumour is the most relevant point
in breast carcinogenesis, as discussed above. Also corrections fac-
tors for the uncertainty margin can be included. This research will
aid clinical decision making regarding screening strategy and
counselling for previously treated HL patients, and the treatment
(modality) strategy for future patients.
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